Role of ErbB/Stat3 in the establishment and progression of pancreatic cancer

ErbB/Stat3 在胰腺癌发生和进展中的作用

基本信息

项目摘要

DESCRIPTION (provided by applicant): Pancreatic adenocarcinomas (PDAC) are the 4th leading cause of cancer deaths in the western world and have the worst prognosis of any cancer with a five-year survival of less than 5%. PDAC develops from pre-neoplasia through various stages of non-invasive neoplastic lesions called PanIN to invasive carcinoma. Current treatments of invasive PDAC including the addition of new biologically targeted therapies to chemotherapy have little impact on overall survival. This R21 proposal focuses at better understanding how initiating oncogenic mutations found in PanIN lesions alter cell signaling pathways, how these pathways influence the phenotype of the cell and whether targeting these pathways will prevent the progression of early lesions to invasive carcinoma. In this context, we found using novel PanIN models from transgenic mice and from human pancreas cells that aberrant activities of erbB kinases and STAT3 occur in early stage PanlN lesions. We will test the hypothesis that hyperactivity of erbB kinases causing aberrant and constitutive activation of STAT3 are early events in pancreatic carcinogenesis and that synergy between these molecular events leads to the establishment of intraductal neoplastic lesions (PanIN) and are required for the progression of these lesions to invasive carcinoma. Two specific aims are proposed. (1) To establish the functional relationship between erbB kinases and STAT3 activation in mediating the tumorigenic properties of PanIN. In this aim the roles of erbB kinase signaling and STAT3 transcriptional activities in mediating the tumorigenic properties of PanIN will be determined, (2) Determine in vivo, whether functional blockade of signaling by erbB kinases and/or STAT3 activity prevents the establishment and/or progression of PanIN to invasive carcinoma. This aim will use in vivo models to determine whether inhibiting erbB kinases and STAT3 activities prevent the establishment and progression of PanIN lesions. In addition, studies will assess whether inhibiting erbB kinases and/or STAT3 are sufficient in vivo for preventing the activation of down stream molecular targets and whether the activation status of these targets are predictors of response to therapy. Overall, these studies will use innovative models to provide a better understanding of the mechanisms involved in the establishment and progression of PDAC and determine whether this information can be translated to prevention or therapy using clinically relevant drugs.
描述(申请人提供):胰腺癌(PDAC)是西方世界癌症死亡的第四大原因,是五年生存率低于5%的癌症中预后最差的。PDAC从癌前病变经过称为Panin的非侵袭性肿瘤性病变的不同阶段发展到浸润性癌。目前侵袭性PDAC的治疗,包括在化疗的基础上增加新的生物靶向治疗,对总体存活率几乎没有影响。这项R21建议的重点是更好地了解在Panin病变中发现的启动癌基因突变如何改变细胞信号通路,这些通路如何影响细胞的表型,以及靶向这些通路是否会防止早期病变发展为浸润性癌。在此背景下,我们从转基因小鼠和人类胰腺细胞中发现了新的Panin模型,在早期PanLN病变中发生了erb B激酶和STAT3的异常活性。我们将检验这样一种假设,即导致STAT3异常和结构性激活的erb B激酶过度激活是胰腺癌发生的早期事件,这些分子事件之间的协同作用导致导管内肿瘤病变(Panin)的建立,并且是这些病变发展为浸润性癌所必需的。提出了两个具体目标。(1)建立erbB激酶和STAT3激活在介导Panin致癌作用中的功能关系。为了达到这个目的,我们将确定erbB激酶信号和STAT3转录活性在介导Panin致癌特性中的作用,(2)在体内确定,通过erbB激酶和/或STAT3活性对信号的功能性阻断是否可以阻止Panin向侵袭性癌的建立和/或进展。这一目标将使用体内模型来确定抑制erbB激酶和STAT3活性是否可以阻止Panin病变的建立和进展。此外,研究将评估体内抑制erbB激酶和/或STAT3是否足以防止下游分子靶点的激活,以及这些靶点的激活状态是否可以预测治疗反应。总体而言,这些研究将使用创新的模型来更好地了解PDAC的建立和发展所涉及的机制,并确定这些信息是否可以转化为使用临床相关药物进行预防或治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James W. Freeman其他文献

Interdisciplinary collaboration within project-level NEPA teams in the US Forest Service
美国林务局项目级 NEPA 团队内的跨学科合作
  • DOI:
    10.1080/09640568.2010.525024
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    0
  • 作者:
    James W. Freeman;M. Stern;M. Mortimer;D. Blahna;L. Cerveny
  • 通讯作者:
    L. Cerveny
Nursing home performance under case-mix reimbursement: responding to heavy-care incentives and market changes.
案例组合报销下的疗养院绩效:应对重症护理激励和市场变化。
  • DOI:
  • 发表时间:
    1998
  • 期刊:
  • 影响因子:
    3.4
  • 作者:
    Mark A. Davis;James W. Freeman;Eric C. Kirby
  • 通讯作者:
    Eric C. Kirby

James W. Freeman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James W. Freeman', 18)}}的其他基金

Role of CD44 in adaptive plasticity of pancreatic cancer
CD44在胰腺癌适应性可塑性中的作用
  • 批准号:
    9339582
  • 财政年份:
    2015
  • 资助金额:
    $ 20.44万
  • 项目类别:
Role of CD44 in adaptive plasticity of pancreatic cancer
CD44在胰腺癌适应性可塑性中的作用
  • 批准号:
    8925205
  • 财政年份:
    2015
  • 资助金额:
    $ 20.44万
  • 项目类别:
Role of Ron kinase in pancreatic cancer
Ron 激酶在胰腺癌中的作用
  • 批准号:
    8696795
  • 财政年份:
    2011
  • 资助金额:
    $ 20.44万
  • 项目类别:
Role of Ron kinase in pancreatic cancer
Ron 激酶在胰腺癌中的作用
  • 批准号:
    8398925
  • 财政年份:
    2011
  • 资助金额:
    $ 20.44万
  • 项目类别:
Role of Ron kinase in pancreatic cancer
Ron 激酶在胰腺癌中的作用
  • 批准号:
    8043361
  • 财政年份:
    2011
  • 资助金额:
    $ 20.44万
  • 项目类别:
Role of Ron kinase in pancreatic cancer
Ron 激酶在胰腺癌中的作用
  • 批准号:
    8245577
  • 财政年份:
    2011
  • 资助金额:
    $ 20.44万
  • 项目类别:
Role of ErbB/Stat3 in the establishment and progression of pancreatic cancer
ErbB/Stat3 在胰腺癌发生和进展中的作用
  • 批准号:
    7191970
  • 财政年份:
    2007
  • 资助金额:
    $ 20.44万
  • 项目类别:
TGF-B RECEPTOR ALTERATIONS AND PANCREAS CANCER
TGF-B 受体改变与胰腺癌
  • 批准号:
    2394324
  • 财政年份:
    1997
  • 资助金额:
    $ 20.44万
  • 项目类别:
TGF-B RECEPTOR ALTERATIONS AND PANCREAS CANCER
TGF-B 受体改变与胰腺癌
  • 批准号:
    6172812
  • 财政年份:
    1997
  • 资助金额:
    $ 20.44万
  • 项目类别:
Role of TGFB Receptor Alterations in Pancreatic Cancer
TGFB 受体改变在胰腺癌中的作用
  • 批准号:
    6579965
  • 财政年份:
    1997
  • 资助金额:
    $ 20.44万
  • 项目类别:

相似海外基金

Analysis of the antioxidant function of xCT in lymphatic endothelial cells and its significance in oral squamous cell carcinoma.
淋巴管内皮细胞xCT抗氧化功能分析及其在口腔鳞癌中的意义
  • 批准号:
    23K16139
  • 财政年份:
    2023
  • 资助金额:
    $ 20.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Use of Peripheral Blood Mononuclear Cells Mitochondrial DNA Content to Detect Hepatocellular Carcinoma in Hepatitis B Virus Infected Nigerians.
利用外周血单核细胞线粒体 DNA 含量检测乙型肝炎病毒感染的尼日利亚人的肝细胞癌。
  • 批准号:
    10734089
  • 财政年份:
    2023
  • 资助金额:
    $ 20.44万
  • 项目类别:
Neoantigen-specific T cells in a novel cutaneous squamous cell carcinoma model
新型皮肤鳞状细胞癌模型中的新抗原特异性 T 细胞
  • 批准号:
    10602966
  • 财政年份:
    2023
  • 资助金额:
    $ 20.44万
  • 项目类别:
Effects of oral squamous carcinoma cells-derived exosomes on pre-metastatic niche formation in cervical lymph nodes
口腔鳞癌细胞来源的外泌体对颈部淋巴结转移前生态位形成的影响
  • 批准号:
    22K10194
  • 财政年份:
    2022
  • 资助金额:
    $ 20.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Targeting Hepatocellular Carcinoma using Vd1 gamma delta T cells engineered with a DAP12-based chimeric receptor
使用基于 DAP12 的嵌合受体改造的 Vd1 γ δ T 细胞靶向肝细胞癌
  • 批准号:
    486272
  • 财政年份:
    2022
  • 资助金额:
    $ 20.44万
  • 项目类别:
    Studentship Programs
MicroRNA-15a/16-mediated cytokine/chemokine reprogramming in Kupffer cells prevents the development of hepatocellular carcinoma
MicroRNA-15a/16 介导的库普弗细胞细胞因子/趋化因子重编程可预防肝细胞癌的发展
  • 批准号:
    10518314
  • 财政年份:
    2022
  • 资助金额:
    $ 20.44万
  • 项目类别:
PARP inhibitor resistance in cancer stem cells in hepatocelular carcinoma
肝细胞癌中癌症干细胞对 PARP 抑制剂的耐药性
  • 批准号:
    22K08023
  • 财政年份:
    2022
  • 资助金额:
    $ 20.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
MicroRNA-15a/16-mediated cytokine/chemokine reprogramming in Kupffer cells prevents the development of hepatocellular carcinoma
MicroRNA-15a/16 介导的库普弗细胞细胞因子/趋化因子重编程可预防肝细胞癌的发展
  • 批准号:
    10688153
  • 财政年份:
    2022
  • 资助金额:
    $ 20.44万
  • 项目类别:
CD147-CAR-NK Cells for Hepatocellular Carcinoma Treatment
CD147-CAR-NK 细胞用于肝细胞癌治疗
  • 批准号:
    10356640
  • 财政年份:
    2022
  • 资助金额:
    $ 20.44万
  • 项目类别:
CD147-CAR-NK Cells for Hepatocellular Carcinoma Treatment
CD147-CAR-NK 细胞用于肝细胞癌治疗
  • 批准号:
    10547810
  • 财政年份:
    2022
  • 资助金额:
    $ 20.44万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了